SEC Form 4 · accession 0001209191-16-128570
Karyopharm Therapeutics Inc. · KPTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Deepika Pakianathan
Director
Period of report
Jun 16, 2016
Accepted (ET)
Jun 17, 2016 · 4:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001503802
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nonstatutory Stock Option (right to buy)F2,F1 | $8.06 | Jun 16, 2016 | A | 10,000 | A | — | Jun 15, 2026 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1This option vests as to 100% of the underlying shares on June 16, 2017, provided that the holder continues to serve as a director of the issuer through such date.
- F2Pursuant to the Delphi Management Partners, VIII, L.L.C. ("DMP VIII") LLC Agreement, the Reporting Person is deemed to hold the options for the benefit of DMP VIII, which is entitled to hold the shares upon issuance. DMP VIII may be deemed the indirect beneficial owner of such shares, and the Reporting Person is a managing member of DMP VIII and may be deemed to share voting and dispositive power over shares held by DMP VIII. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.